FOXN2, identified as a novel biomarker in serum, modulates the transforming growth factor-beta signaling pathway through its interaction with partitioning defective 6 homolog alpha, contributing to the pathogenesis of gastric cancer.

Liang LiXueFeng SunMei ZhangBangShuo ZhangYi YangSheng Wang

Published in: Growth factors (Chur, Switzerland) (2024)

In summary, our data suggest that FOXN2 acts as an oncogenic factor in GC, modulating the TGFβ pathway by binding to PARD6A, thereby influencing gastric carcinogenesis. This study underscores the functional significance of FOXN2 as a potential serum biomarker and therapeutic target in GC.

Keyphrases

transforming growth factor
epithelial mesenchymal transition
signaling pathway
pi k akt
gas chromatography
electronic health record
transcription factor
induced apoptosis
data analysis
risk assessment
climate change
artificial intelligence